Teddy’s Radiopharmaceutical Bioanalysis Platform has established a dedicated radiopharmaceutical laboratory of over 30 m² in Wuxi and holds a Class II Radiation Safety License. The laboratory is approved for handling up to 10 radionuclides, including C-14, Cu-64, Zr-89, Y-90, In-111, I-131, Lu-177, Pb-212, Ac-225, and Th-227, enabling sponsors to access comprehensive, one-stop services for innovative radiopharmaceutical development.

The platform is equipped with gamma counters, liquid scintillation counters, and online HPLC radio-detection systems, providing integrated capabilities for pharmacokinetic studies, dosimetry assessment, urinary excretion analysis, and data interpretation to support clinical research of novel radiopharmaceuticals.

Teddy is supported by an experienced team of radiopharmaceutical laboratory specialists and can deploy qualified technical staff to nuclear medicine departments as required, delivering on-site testing and related technical support services.

In addition, the radiopharmaceutical laboratory offers radiolabeled human AME studies for innovative drugs, including mass balance assessment, radioactive pharmacokinetics, metabolite profiling, metabolite identification, and non-radiolabeled pharmacokinetic analysis.